ELISA/assay

Human Parkinson disease 2/parkin ELISA Kit

MBS732278

48-Strip-Wells

470 USD

ELISA Kit

Human Parkinson disease 2/parkin ELISA Kit

Parkinson disease 2/parkin

Human Parkinson disease 2/parkin ELISA Kit; Parkinson disease 2/parkin; Parkinson disease 2/parkin (Human)

PARK2 protein; E3 ubiquitin-protein ligase parkin; E3 ubiquitin-protein ligase parkin; parkin 2; OTTHUMP00000017562; OTTHUMP00000017563; OTTHUMP00000017564; OTTHUMP00000017565; OTTHUMP00000017566; OTTHUMP00000017567; E3 ubiquitin ligase; parkinson disease protein 2; parkinson juvenile disease protein 2; Parkinson disease (autosomal recessive, juvenile) 2, parkin; parkinson protein 2, E3 ubiquitin protein ligase (parkin); Parkinson juvenile disease protein 2

Park2

PARK2; PARK2; PDJ; PRKN; AR-JP; LPRS2; PRKN

PRKN2_HUMAN

Human

This assay has high sensitivity and excellent specificity for detection of PARK2. No significant cross-reactivity or interference between PARK2 and analogues was observed. NOTE: Limited by current skills and knowledge, it is impossible for us to complete the cross-reactivity detection between PARK2 and all the analogues, therefore, cross reaction may still exist in some cases.

Store all reagents at 2-8 degree C

Samples: Serum, plasma, cell culture supernatants, body fluid and tissue homogenate. Assay Type: Sandwich. Sensitivity: 1.0pg/mL.

Human ELISA Kit

Intended Uses: This PARK2 ELISA kit is a 1.5 hour solid-phase ELISA designed for the quantitative determination of Human PARK2. This ELISA kit for research use only, not for therapeutic or diagnostic applications!. Principle of the Assay PARK2 ELISA kit applies the quantitative sandwich enzyme immunoassay technique. The microtiter plate has been pre-coated with a monoclonal antibody specific for PARK2. Standards or samples are then added to the microtiter plate wells and PARK2 if present, will bind to the antibody pre-coated wells. In order to quantitatively determine the amount of PARK2 present in the sample, a standardized preparation of horseradish peroxidase (HRP)-conjugated polyclonal antibody, specific for PARK2 are added to each well to "sandwich" the PARK2 immobilized on the plate. The microtiter plate undergoes incubation, and then the wells are thoroughly washed to remove all unbound components. Next, substrate solutions are added to each well. The enzyme (HRP) and substrate are allowed to react over a short incubation period. Only those wells that contain PARK2 and enzyme-conjugated antibody will exhibit a change in color. The enzyme-substrate reaction is terminated by addition of a sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450 nm. A standard curve is plotted relating the intensity of the color (O.D.) to the concentration of standards. The PARK2 concentration in each sample is interpolated from this standard curve.

18314633

O60260

51,641 Da

Adaptive Immunity Signaling Pathway (366160); Alpha-synuclein Signaling Pathway (137913); Antigen Processing: Ubiquitination Proteasome Degradation Pathway (366162); Class I MHC Mediated Antigen Processing Presentation Pathway (366161); Immune System Pathway (106386); Parkinson's Disease Pathway (83098); Protein Processing In Endoplasmic Reticulum Pathway (167325); Protein Processing In Endoplasmic Reticulum Pathway (167190); Ubiquitin Mediated Proteolysis Pathway (83056); Ubiquitin Mediated Proteolysis Pathway (466)

The precise function of this gene is unknown; however, the encoded protein is a component of a multiprotein E3 ubiquitin ligase complex that mediates the targeting of substrate proteins for proteasomal degradation. Mutations in this gene are known to cause Parkinson disease and autosomal recessive juvenile Parkinson disease. Alternative splicing of this gene produces multiple transcript variants encoding distinct isoforms. Additional splice variants of this gene have been described but currently lack transcript support. [provided by RefSeq]

PARK2: a component of a multiprotein E3 ubiquitin ligase complex, catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins, such as BCL2, SYT11, CCNE1, GPR37, STUB1, a 22 kDa O-linked glycosylated isoform of SNCAIP, SEPT5, ZNF746 and AIMP2. Mediates monoubiquitination as well as Lys-48 -linked and Lys-63 -linked polyubiquitination of substrates depending on the context. Participates in the removal and/or detoxification of abnormally folded or damaged protein by mediating Lys-63 -linked polyubiquitination of misfolded proteins such as PARK7: Lys-63 - linked polyubiquitinated misfolded proteins are then recognized by HDAC6, leading to their recruitment to aggresomes, followed by degradation. Mediates Lys-63 -linked polyubiquitination of SNCAIP, possibly playing a role in Lewy-body formation. Mediates monoubiquitination of BCL2, thereby acting as a positive regulator of autophagy. Promotes the autophagic degradation of dysfunctional depolarized mitochondria. Mediates Lys-48 -linked polyubiquitination of ZNF746, followed by degradation of ZNF746 by the proteasome; possibly playing a role in role in regulation of neuron death. Limits the production of reactive oxygen species (ROS). Loss of this ubiquitin ligase activity appears to be the mechanism underlying pathogenesis of PARK2. May protect neurons against alpha synuclein toxicity, proteasomal dysfunction, GPR37 accumulation, and kainate-induced excitotoxicity. May play a role in controlling neurotransmitter trafficking at the presynaptic terminal and in calcium-dependent exocytosis. Regulates cyclin-E during neuronal apoptosis. May represent a tumor suppressor gene. Forms an E3 ubiquitin ligase complex with UBE2L3 or UBE2L6. Mediates Lys-63 -linked polyubiquitination by associating with UBE2V1. Part of a SCF-like complex, consisting of PARK2, CUL1 and FBXW7. Part of a complex, including STUB1, HSP70 and GPR37. The amount of STUB1 in the complex increases during ER stress. STUB1 promotes the dissociation of HSP70 from PARK2 and GPR37, thus facilitating PARK2-mediated GPR37 ubiquitination. HSP70 transiently associates with unfolded GPR37 and inhibits the E3 activity of PARK2, whereas, STUB1 enhances the E3 activity of PARK2 through promotion of dissociation of HSP70 from PARK2-GPR37 complexes. Interacts with PSMD4 and PACRG. Interacts with LRRK2. Interacts with RANBP2. Interacts with SUMO1 but not SUMO2, which promotes nuclear localization and autoubiquitination. Interacts (via first RING- type domain) with AIMP2 (via N-terminus). Interacts with PSMA7 and RNF41. Interacts with PINK1. Highly expressed in the brain including the substantia nigra. Expressed in heart, testis and skeletal muscle. Expression is down-regulated or absent in tumor biopsies, and absent in the brain of PARK2 patients. Overexpression protects dopamine neurons from kainate-mediated apoptosis. Found in serum. Belongs to the RBR family. Parkin subfamily. 6 isoforms of the human protein are produced by alternative splicing. Protein type: Ubiquitin ligase; Ligase; EC 6.3.2.19; EC 6.3.2.-; Ubiquitin conjugating system. Chromosomal Location of Human Ortholog: 6q25.2-q27. Cellular Component: Golgi apparatus; neuron projection; mitochondrion; perinuclear region of cytoplasm; endoplasmic reticulum; cytoplasm; SCF ubiquitin ligase complex; nucleus; cytosol; ubiquitin ligase complex. Molecular Function: tubulin binding; identical protein binding; ubiquitin binding; zinc ion binding; histone deacetylase binding; ubiquitin-protein ligase activity; Hsp70 protein binding; actin binding; protein kinase binding; PDZ domain binding; protein binding; G-protein-coupled receptor binding; ubiquitin conjugating enzyme binding; heat shock protein binding; ubiquitin protein ligase binding; chaperone binding; kinase binding; SH3 domain binding; ligase activity. Biological Process: protein monoubiquitination; proteasomal ubiquitin-dependent protein catabolic process; negative regulation of JNK cascade; negative regulation of actin filament bundle formation; central nervous system development; startle response; protein polyubiquitination; regulation of protein ubiquitination; adult locomotory behavior; protein ubiquitination during ubiquitin-dependent protein catabolic process; regulation of neurotransmitter secretion; protein ubiquitination; mitochondrion localization; norepinephrine metabolic process; dopamine metabolic process; regulation of dopamine secretion; negative regulation of insulin secretion; negative regulation of glucokinase activity; zinc ion homeostasis; regulation of lipid transport; negative regulation of protein amino acid phosphorylation; dopamine uptake; negative regulation of neuron apoptosis; positive regulation of DNA binding; synaptic transmission, glutamatergic; mitochondrial fission; mitochondrion organization and biogenesis; protein autoubiquitination; positive regulation of I-kappaB kinase/NF-kappaB cascade; protein stabilization; transcription, DNA-dependent; learning; regulation of protein transport; cellular protein catabolic process; positive regulation of proteasomal ubiquitin-dependent protein catabolic process; mitochondrion degradation; regulation of autophagy; positive regulation of transcription from RNA polymerase II promoter; response to oxidative stress. Disease: Parkinson Disease 2, Autosomal Recessive Juvenile; Leprosy, Susceptibility To, 2; Lung Cancer; Ovarian Cancer

48-Strip-Wells

470 USD

96-Strip-Wells

675